2026-03-19

Some interesting research was published in JAMA Surgery journal in 2025. 

The research related to real life GLP-1 use with comparison to Bariatric Surgery outcomes over a two year period.  These were real patients with severe obesity undergoing treatment options, not part of a trial cohort nor any other highly selected group or controlled environment.

Considering only patients with BMI above 40 with available weight loss data there were:

  • 257 patients taking GLP-1 agents included
  • 1291 patients having bariatric surgery included
 

 

Over two years of treatment the following was found:

  • Bariatric Surgery patients lost 28.3% of their total starting weight compared to 10.3% for GLP-1 patients
  • Between half and two thirds of the GLP-1 patients discontinued treatment within the first year
  • Bariatric Surgery patients required less hospital stay, less emergency department visits and less outpatient clinic visits over this two year period
  • Overall treatment related costs over two years ended up higher for the GLP-1 group

 

Comment

Obesity is a chronic, lifelong disease process which requires lifelong intervention.

Although the current generation of GLP-1 agents are exciting and promising, at this stage it is also true to say that their long term efficacy has yet to be established and long term side effects are unknown.

 

REFERENCE

JAMA Surg. 2025;160(11):1232-1239. doi:10.1001/jamasurg.2025.3590

Published online September 17, 2025.

Back to News